{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:19:51Z","timestamp":1762867191454},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the relationship between macular telangiectasia Type 2 and systemic levels of sex steroids or their antagonization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In a prospective single-center study, 90 patients with macular telangiectasia Type 2 were investigated. Female patients were evaluated for previous surgical (e.g., ovariectomy) and\/or pharmacological (e.g., aromatase inhibitors, tamoxifen) therapy resulting in reduced action of sex steroids. In males, free serum testosterone levels were assessed in patients and controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fourteen of 49 (29%) female patients had a history of pharmacological suppression of sex steroids and\/or ovariectomy. These patients were younger at disease onset when compared with those without such medical history (mean \u00b1 SD: 47.1 \u00b1 7.8, range: 38\u201359, versus 60.1 \u00b1 7.6, range: 45\u201376; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Male patients showed significantly lower free serum testosterone levels compared with controls at younger age (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001 and 0.04 in the first and second age quartiles, respectively), as opposed to nonsignificant differences in older patients. In men \u2264 60 years of age, a biochemical hypogonadism (free serum testosterone &lt; 0.05 ng\/mL) was present in 53% (8\/15) and 4% (2\/49) of patients and controls, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results indicate that steroidal sex hormones might be involved in the presumably multifactorial pathophysiology of macular telangiectasia Type 2.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001789","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T22:22:43Z","timestamp":1503526963000},"page":"S61-S66","source":"Crossref","is-referenced-by-count":5,"title":["SEX STEROIDS AND MACULAR TELANGIECTASIA TYPE 2"],"prefix":"10.1097","volume":"38","author":[{"given":"Simone","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Allam","sequence":"additional","affiliation":[{"name":"Department of Dermatology\/Andrology Unit, University of Bonn, Bonn, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Bunzek","sequence":"additional","affiliation":[{"name":"Department of Dermatology\/Andrology Unit, University of Bonn, Bonn, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter CHARBEL","family":"Issa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany;"},{"name":"Oxford Eye Hospital, OUH NHS Foundation Trust and the Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","article-title":"Macular telangiectasia type 2","volume":"34","author":"Charbel Issa","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ajo.2005.04.042","article-title":"Optical coherence tomography findings in tamoxifen retinopathy","volume":"140","author":"Gualino","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-006-9187-y","article-title":"Optical coherence tomography in tamoxifen retinopathy","volume":"99","author":"Mauget-Faysse","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00347-007-1677-8","article-title":"Tamoxifen retinopathy: a case series of clinical and functional data [in German]","volume":"105","author":"Ritter","year":"2008","journal-title":"Ophthalmologe"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00347-010-2150-7","article-title":"Unusual symptoms for tamoxifen-associated maculopathy [in German]","volume":"107","author":"Hager","year":"2010","journal-title":"Ophthalmologe"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ajo.2014.02.046","article-title":"Pseudocystic foveal cavitation in tamoxifen retinopathy","volume":"157","author":"Doshi","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/IAE.0000000000000082","article-title":"First symptoms and their age of onset in macular telangiectasia type 2","volume":"34","author":"Heeren","year":"2014","journal-title":"Retina"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1046\/j.1365-2265.2003.01772.x","article-title":"Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men","volume":"58","author":"Diver","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13685539909003173","article-title":"A new \u201caging males\u201d symptoms' rating scale","volume":"2","author":"Heinemann LAJ","year":"1999","journal-title":"Aging Male"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ophtha.2009.05.010","article-title":"Familial asymptomatic macular telangiectasia type 2","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1136\/bjo.2007.115675","article-title":"Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins","volume":"91","author":"Hannan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0002-9394(99)00380-3","article-title":"Bilateral juxtafoveolar telangiectasis in monozygotic twins","volume":"129","author":"Menchini","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ajo.2004.09.030","article-title":"Group 2A idiopathic juxtafoveolar retinal telangiectasia in monozygotic twins","volume":"139","author":"Siddiqui","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ng.3799","article-title":"Genome-wide analyses identify common variants associated with macular telangiectasia type 2","volume":"49","author":"Scerri","year":"2017","journal-title":"Nat Genet"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog Brain Res"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cns.12538","article-title":"Neuroprotective role of steroidal sex hormones: an overview","volume":"22","author":"Siddiqui","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2015.12.044","article-title":"From the 90's to now: a brief historical perspective on more than two decades of estrogen neuroprotection","volume":"1633","author":"Engler-Chiurazzi","year":"2016","journal-title":"Brain Res"},{"key":"R21-20230816","first-page":"2105","article-title":"Estrogen receptor expression in bovine and rat retinas","volume":"39","author":"Kobayashi","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1034\/j.1600-0420.2000.078002146.x","article-title":"Identification of androgen, estrogen and progesterone receptor mRNAs in the eye","volume":"78","author":"Wickham","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.exer.2007.02.008","article-title":"17beta-estradiol synthesis in the adult male rat retina","volume":"85","author":"Cascio","year":"2007","journal-title":"Exp Eye Res"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.steroids.2015.08.002","article-title":"The estrogenic retina: the potential contribution to healthy aging and age-related neurodegenerative diseases of the retina","volume":"103","author":"Cascio","year":"2015","journal-title":"Steroids"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s11064-009-0092-8","article-title":"Sex steroids inhibit osmotic swelling of retinal glial cells","volume":"35","author":"Neumann","year":"2010","journal-title":"Neurochem Res"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrn3856","article-title":"The neuroprotective actions of oestradiol and oestrogen receptors","volume":"16","author":"Arevalo","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/02713683.2014.925933","article-title":"Estrogen signalling in the pathogenesis of age-related macular degeneration","volume":"40","author":"Kaarniranta","year":"2015","journal-title":"Curr Eye Res"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2004.06.067","article-title":"Effects of neurosteroids on ischemia-reperfusion injury in the rat retina: role of sigma 1 recognition sites","volume":"498","author":"Bucolo","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0079-6123(08)01144-8","article-title":"17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat","volume":"173","author":"Russo","year":"2008","journal-title":"Prog Brain Res"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12031-014-0384-6","article-title":"17beta-estradiol ameliorates light-induced retinal damage in Sprague-Dawley rats by reducing oxidative stress","volume":"55","author":"Wang","year":"2015","journal-title":"J Mol Neurosci"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bjo.65.3.177","article-title":"Tamoxifen retinopathy","volume":"65","author":"McKeown","year":"1981","journal-title":"Br J Ophthalmol"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ajo.2007.03.023","article-title":"Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy","volume":"144","author":"Bourla","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R33-20230816","first-page":"315","article-title":"Tamoxifen retinopathy","volume":"62","author":"Kaiser-Kupfer","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(19920615)69:12<2961::AID-CNCR2820691215>3.0.CO;2-W","article-title":"Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients","volume":"69","author":"Pavlidis","year":"1992","journal-title":"Cancer"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0002-9394(99)80190-1","article-title":"Long-term tamoxifen citrate use and potential ocular toxicity","volume":"125","author":"Gorin","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0002-9394(14)70321-6","article-title":"Screening for ocular toxicity in asymptomatic patients treated with tamoxifen","volume":"117","author":"Heier","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0773.2002.910305.x","article-title":"Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells","volume":"91","author":"Maenpaa","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0039-128X(01)00133-7","article-title":"Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions","volume":"67","author":"Lonard","year":"2002","journal-title":"Steroids"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1996.14.3.1018","article-title":"Tamoxifen-associated eye disease. A review","volume":"14","author":"Nayfield","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201801001-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T23:03:41Z","timestamp":1692227021000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201801001-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001789","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}